FDA clears Spacelabs' EFM Visualization used in Anesthesia System

OSI Systems, Inc. (NASDAQ:OSIS), a vertically-integrated provider of specialized electronic products for critical applications in the Security and Healthcare industries, today announced that its Healthcare division, Spacelabs Healthcare, has received FDA 510k clearance for Enhanced Flow Meter (EFM) Visualization which will be utilized on the BleaseSirius Anesthesia System. EFM's unique visualization feature provides the "touch and feel" to which clinicians are accustomed by displaying an easy to read format using 3-D gas flow tubes and numerical data. With the EFM, the patient data becomes immediately available for export to patient monitoring and hospital information systems.

OSI Systems' CEO, Deepak Chopra, stated, "We are excited to receive FDA clearance for our Enhanced Flow Meter incorporating cutting edge technology. With several upcoming new product introductions in patient monitoring, anesthesia, cardiology, and data connectivity, we continue to innovate across all of our product platforms and provide hospitals with integrated solutions utilizing the latest technology and help deliver improved patient care."

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

Sign in to keep reading

We're committed to providing free access to quality science. By registering and providing insight into your preferences you're joining a community of over 1m science interested individuals and help us to provide you with insightful content whilst keeping our service free.

or

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Scaling organ‑chip technology for human‑relevant drug discovery